CHMP2B-related frontotemporal dementia

*CHMP2B-*related frontotemporal dementia is a progressive brain disorder that affects personality, behavior, and language. The symptoms of this disorder usually become noticeable in a person's fifties or sixties, and affected people survive about 3 to 21 years after the appearance of symptoms.

Changes in personality and behavior are the most common early signs of *CHMP2B*-related frontotemporal dementia. These changes include inappropriate emotional responses, restlessness, loss of initiative, and neglect of personal hygiene. Affected individuals may overeat sweet foods or place non-food items into their mouths (hyperorality). Additionally, it may become difficult for affected individuals to interact with others in a socially appropriate manner. They increasingly require help with personal care and other activities of daily living.

Many people with *CHMP2B*-related frontotemporal dementia develop progressive problems with speech and language (aphasia). They may have trouble speaking, although they can often understand others' speech and written text. Affected individuals may also have difficulty using numbers (dyscalculia). In the later stages of the disease, many completely lose the ability to communicate.

Several years after signs and symptoms first appear, some people with *CHMP2B*-related frontotemporal dementia develop problems with movement. These movement abnormalities include rigidity, tremors, uncontrolled muscle tensing (dystonia), and involuntary muscle spasms (myoclonus). As the disease progresses, most affected individuals become unable to walk.

**Frequency**

*CHMP2B*-related frontotemporal dementia has been reported in one large family in Denmark and a few unrelated individuals from other countries. This disease appears to be a rare form of frontotemporal dementia.

**Causes**

*CHMP2B*-related frontotemporal dementia results from mutations in the *CHMP2B* gene. This gene provides instructions for making a protein called charged multivesicular body protein 2B. This protein is active in the brain, where it plays an essential role in transporting proteins that need to be broken down (degraded).

Mutations in the *CHMP2B* gene lead to the production of an abnormal version of charged multivesicular body protein 2B. Most of the mutations that cause *CHMP2B*-related frontotemporal dementia result in the production of an abnormal protein that is missing a critical segment at one end. This segment keeps the protein turned off
(inactive) when it is not needed. Without this segment, the protein is constantly turned on (active), which disrupts the transport and degradation of other proteins. These abnormalities ultimately lead to the death of nerve cells (neurons) in the brain.

A gradual loss of neurons throughout the brain is characteristic of CHMP2B-related frontotemporal dementia. Many of the features of this disease result from neuronal death in regions near the front of the brain called the frontal and temporal lobes. The frontal lobes are involved in reasoning, planning, judgment, and problem-solving, while the temporal lobes help process hearing, speech, memory, and emotion. It is unclear why the signs and symptoms of this disease are related primarily to the frontal and temporal lobes.

**Inheritance Pattern**

This condition is inherited in an autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to cause the disorder.

**Other Names for This Condition**

- chromosome 3-linked frontotemporal dementia
- DTM1
- FTD-3
- FTD-CHMP2B
- FTD3

**Diagnosis & Management**

**Formal Treatment/Management Guidelines**

- American Psychiatric Association: Practice Guideline for the Treatment of Patients with Alzheimer's Disease and Other Dementias  

**Genetic Testing Information**

- What is genetic testing?  
  /primer/testing/genetictesting

- Genetic Testing Registry: Frontotemporal Dementia, Chromosome 3-Linked  

**Research Studies from ClinicalTrials.gov**

- ClinicalTrials.gov  
  https://clinicaltrials.gov/ct2/results?cond=%22CHMP2B-related+frontotemporal+dementia%22+OR+%22Frontotemporal+Dementia%22
Other Diagnosis and Management Resources

• Family Caregiver Alliance
  https://www.caregiver.org/frontotemporal-dementia

• GeneReview: Frontotemporal Dementia, Chromosome 3-Linked
  https://www.ncbi.nlm.nih.gov/books/NBK1199

Additional Information & Resources

Health Information from MedlinePlus

• Encyclopedia: Dementia
  https://medlineplus.gov/ency/article/000739.htm

• Encyclopedia: Lobes of the Brain
  https://medlineplus.gov/ency/imagepages/9549.htm

• Health Topic: Dementia
  https://medlineplus.gov/dementia.html

Additional NIH Resources

• National Institute of Neurological Disorders and Stroke
  https://www.ninds.nih.gov/Disorders/All-Disorders/Frontotemporal-Dementia-Information-Page

Educational Resources

• MalaCards: chmp2b-related frontotemporal dementia
  https://www.malacards.org/card/chmp2b_related_frontotemporal_dementia

• Merck Manual Consumer Version

• Northwestern University
  https://www.brain.northwestern.edu/dementia/ftd/index.html

• Orphanet: Frontotemporal dementia
  https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=282

• University of California, San Francisco Memory and Aging Center
  https://memory.ucsf.edu/dementia/ftd

Patient Support and Advocacy Resources

• Association for Frontotemporal Degeneration
  https://www.theaftd.org/

• Family Caregiver Alliance
  https://www.caregiver.org/frontotemporal-dementia
Clinical Information from GeneReviews

- Frontotemporal Dementia, Chromosome 3-Linked
  https://www.ncbi.nlm.nih.gov/books/NBK1199

Scientific Articles on PubMed

- PubMed
  https://www.ncbi.nlm.nih.gov/pubmed?term=%28%28chromosome+3-linked+frontotemporal+dementia%5BTIAB%5D%29+OR+%28ftd-3%5BTIAB%5D%29+OR+%28ftd-chmp2b%5BTIAB%5D%29+OR+%28%28CHMP2B%5BTIAB%5D%29+AND+%28frontotemporal+dementia%5BTIAB%5D%29%29+AND+english%5Bla%5D+AND+human%5Bmh%5D+AND+%22last+3600+days%22%5Bdp%5D

Catalog of Genes and Diseases from OMIM

- FRONTOTEMPORAL DEMENTIA, CHROMOSOME 3-LINKED
  http://omim.org/entry/600795

Sources for This Summary

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/8541850

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15178935

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/9791535

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12451202

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17917582

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20301378

Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18484988


Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16041373


Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17956895

Reprinted from Genetics Home Reference:

Reviewed: August 2010
Published: January 7, 2020

Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
National Institutes of Health
Department of Health & Human Services